Leadership Perspective:LISTENING & LEARNING FROM THE RARE DISEASE COMMUNITY
IMPROVE THE LIVES OF PEOPLE
WITH SERIOUS DISEASES
With inspiring scientific and patient collaborations and a legacy of cutting-edge, homegrown innovation, we are committed to improving the lives of people with serious diseases by discovering new treatments for unmet medical needs.
Our robust pipeline spans eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.Learn more about our pipeline
We are intent on deepening our strong and sustainable portfolio of innovative medicines. We are improving the traditional drug development process through proprietary technologies that are designed to accelerate the time discovery to drug approval and improve the likelihood of success. We are also leading ambitious initiatives, such as the Regeneron Genetics Center?, one of the largest genetics sequencing efforts in the world.Learn about our technology
We have always approached pricing with fairness, affordability and access at the forefront. We also believe in transparency and work with independent organizations to conduct cost-effectiveness assessments when bringing treatments to market.Learn more about our U.S. Pricing Philosophy
Product Support Programs
We offer product support to both healthcare providers and patients, including contacting patients’ health plans to determine the requirements for coverage and reimbursement and educating healthcare providers about product coverage, reimbursement and claims coding. We offer co-pay assistance to eligible patients, and rebates and discounts to payers to help make our products more affordable.
We also provide patient assistance programs that are designed to increase access to medicine and provide education on using medicines safely and appropriately. Our programs help eligible patients throughout their treatment journey with insurance eligibility support, patient resources, financial assistance and access to free medicine.
Access to Medicines
We are committed to bringing important new medicines to people with serious diseases.
Before a new medicine is widely available to the public, it undergoes rigorous clinical testing to satisfy the safety and efficacy criteria required for regulatory approval. Approval by a country or region's health regulatory authority, such as the U.S. Food and Drug Administration, allows the appropriate group of people to access a medicine.
In some cases, a potentially beneficial therapy may not yet be approved by regulatory authorities. Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a medicine. The patients who receive compassionate use usually have exhausted all, if any, available treatment options and are unable to participate in ongoing clinical trials.Learn more about Compassionate Use Requests
Patient Assistance Foundations
We are committed to ensuring that patients can afford and remain compliant with the therapy that best suits their medical needs. We donate to independent third-party charitable foundations, known as Patient Assistance Foundations, which provide financial assistance to patients who might not otherwise be able to afford their medications. Our charitable contributions support patients without regard to the beneficiary’s choice of product, provider, practitioner, supplier or health plan. We provide guidelines and training to our employees who might engage with the Foundations, and we review our activities regularly to ensure adherence to our guidelines.
Increasing Disease Awareness
We believe patients should be knowledgeable about their disease so they can advocate and make informed decisions around their care. Regeneron supports efforts to empower patients with information to help them better understand and manage their disease. We support organizations that create educational materials and disease management tools for patients and their caregivers. We know that patients are seeking information from the most trusted sources and we want to ensure that there is up-to-date and relevant information wherever they look.
Elevating the Patient Voice
We believe that it is important to include the patient voice early in the R&D and clinical development process. Under the guidance of patient advocacy groups, we bring patients together with our researchers, clinical development colleagues and health economic outcomes research groups to learn what it means to live with a disease, how patients manage their day-to-day lives and what they and their caregivers want in new therapies. Through this process, we have changed and added new outcome measures, or what clinicians call “endpoints,” to our clinical trials and have worked collaboratively to test and develop new patient-reported outcomes that have never been studied in the past.
Read page 33 of our 2019 Responsibility Report to learn how we put our patient advocacy into action.
Supporting Patient Access
We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health. Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health. Regeneron has supported advocacy training, distribution of access tools, town halls and coalition building for patients and caregivers so that they can have a greater chance for successful outcomes.
We are a different kind of biotechnology company with our ethos of ‘Doing Well by Doing Good’. One way to demonstrate our commitment to doing the right thing is through the application of our homegrown technologies and novel science approaches to respond to public health challenges like infectious disease outbreaks.
One of our proudest moments of 2019 was learning that our investigational Ebola therapy, REGN-EB3, was so effective in preventing death compared to the prior antibody standard of care that the PALM clinical trial was halted early. The results, later published in The New England Journal of Medicine, found that REGN-EB3 demonstrated superior efficacy compared to the ZMapp control arm across multiple measures, including the primary endpoint of mortality at day 28 and secondary endpoint of reduction of number of days until the Ebola virus was no longer detected in the bloodstream. Given these groundbreaking results, we are working with the FDA to gain regulatory approval and with U.S. and global health authorities to determine appropriate stockpiling of REGN-EB3.
A cocktail of three antibodies, REGN-EB3 is a prime example of the power of Regeneron’s novel and proprietary VelocImmune? platform and associated VelociSuite technologies to generate and identify potential treatments rapidly, condensing a process that normally takes years into less than 12 months.Learn more about our technologies
Leadership Perspective:MAKING A DRUG YOU HOPE NO ONE WILL EVER NEED
Our COVID-19 Response Efforts
We are applying our more than 30 years of scientific and technology expertise to combat the COVID-19 pandemic. In keeping with our mission and values, when the novel coronavirus, SARS-CoV-2, emerged in late 2019 as a public threat, we asked ourselves again, “what can we do to help?” Building on our Ebola and Middle Eastern Respiratory Syndrome (MERS) coronavirus experience, and using the same VelociSuite? technologies, we are collaborating to rapidly develop a novel antibody cocktail that could be used as a preventative or treatment to combat this latest significant global health risk.Learn more about our response efforts
Leadership Perspective:WORKING TOGETHER TO PROVIDE COVID-19 TESTING COMPONENTS